Oruka Therapeutics' ORKA-001 Shows 100-Day Half-Life in Phase 1 Trial, Potentially Enabling Annual Dosing for Psoriasis
核心洞察
Oruka Therapeutics (搜索) announced interim Phase 1 results showing ORKA-001, its IL-23p19 antibody for plaque psoriasis (搜索), has a confirmed half-life of 100 days, three times longer than AbbVie (搜索)'s Skyrizi.
The extended half-life combined with demonstrated effectiveness could enable once-yearly dosing for psoriasis patients, potentially transforming the current treatment landscape.
The company secured $180 million in private placement funding led by Viking Global Investors (搜索) to support operations through 2027 data readouts.
Oruka Therapeutics (搜索) announced interim results from its Phase 1 trial of ORKA-001, revealing the investigational IL-23p19 antibody has achieved a confirmed half-life of 100 days for treating plaque psoriasis (搜索). This extended duration is three times greater than AbbVie (搜索)'s risankizumab (Skyrizi), potentially positioning ORKA-001 to offer once-yearly dosing to patients with chronic skin diseases.
Extended Half-Life Could Transform Treatment Paradigm
The 100-day half-life of ORKA-001, combined with its demonstrated effectiveness in the Phase 1 trial, represents a significant advancement in psoriasis treatment. Current therapies typically require more frequent dosing schedules, making the prospect of annual administration a potentially transformative development for patients managing this chronic condition.
The long-acting IL-23p19 antibody's extended pharmacokinetic profile could greatly alter the current treatment landscape for plaque psoriasis (搜索) patients, offering improved convenience and potentially better adherence compared to existing therapies that require more frequent administration.
Funding Secured Through 2027 Data Readouts
Concurrent with the clinical announcement, Oruka Therapeutics (搜索) completed a $180 million private placement led by Viking Global Investors (搜索), with participation from both new and existing investors. The company expects to use these funds for research and development activities, general corporate expenses, and working capital needs.
This funding provides Oruka with sufficient resources to continue operations for one year after the anticipated ORKA-002 Phase 2 and ORKA-001 EVERLAST-B Phase 2b data readouts expected in 2027, ensuring the company can advance its clinical programs through key development milestones.
Market Response and Analyst Outlook
Oruka Therapeutics (搜索) stock surged 14.09% following the announcement, with trading volume reaching approximately 300,000 shares compared to the three-month daily average of about 142,000 units. Despite the positive momentum, shares remain down 23.16% year-to-date and 41.29% over the past 12 months.
Wall Street analysts maintain a Strong Buy consensus rating for Oruka Therapeutics (搜索) based on eight Buy ratings issued over the past three months. The average price target of $43.86 represents a potential 158.91% upside from current levels. Clear Street analyst Kaveri Pohlman reiterated a Buy rating with a $46 price target, suggesting 171.55% upside potential.
The company has experienced significant volatility in recent months, with shares climbing 13.3% over the past month and 112.6% over the last quarter, driven by clinical progress with ORKA-001 and the completion of a $756 million shelf registration.